Nolomirole
Nolomirole (CHF 1035) is an orally active and selective DA2 dopaminergic receptor/α2-adrenoceptor agonist. Nolomirole attenuates the heart failure signs in the Monocrotaline (HY-N0750)-induced congestive heart failure model. Nolomirole increases cardiac output.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 90060-42-7
- Fòrmula: C19H27NO4
- Peso molecular:333.42
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Ver todos los productos específicos de isoformas Dopamine Receptor
MoreVer todos los productos específicos de isoformas Adrenergic Receptor
More
Actividad biológica
Descripciòn
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female rats were given single intraperitoneal injection of Monocrotaline (50 mg/kg) [5].
-
Dosage:0.25 mg/kg
-
Administration:Oral gavage (p.o.), twice a day for 21-25 days after Monocrotaline administration 3 days later, and then evaluated heart hypertrophy and neuroendocrine alterations.
-
Result:Significantly reduced hypertrophy of right atria (0.29 mg/g) and ventricles (1.62 mg/g), plasma levels of ANP and presence of pleural/peritoneal effusions and norepinephrine depletion of right ventricle (from 3.64 nmol /gww to 5.56 nmol/gww).
Chemical Information
-
No. CAS 90060-42-7
-
Peso molecular 333.42
-
Fòrmula C19H27NO4
-
SMILES
CC(C)C(OC1=C2C(CC(NC)CC2)=CC=C1OC(C(C)C)=O)=O
-
Synonyms
CHF 1035 free base
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
[1]. 1. Afzal M. Recent updates on novel therapeutic targets of cardiovascular diseases. Mol Cell Biochem. 2021 Jan; 476(1):145-155. [Content Brief]
[2]. 2. Torp-Pedersen C, et al. A randomised trial of a pre-synaptic stimulator of DA2-dopaminergic and alpha2-adrenergic receptors on morbidity and mortality in patients with heart failure. Eur J Heart Fail. 2008 Jan; 10(1):89-95. [Content Brief]
[3]. 3. Tjeerdsma G, et al. Autonomic and hemodynamic effects of a new selective dopamine agonist, CHF1035, in patients with chronic heart failure. Cardiovasc Drugs Ther. 2001 Mar; 15(2):139-45. [Content Brief]
[4]. 4. Pasini E, et al. Effect of nolomirole on monocrotaline-induced heart failure. Pharmacol Res. 2004 Jan; 49(1):1-5. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Nolomirole Related Classifications
HY-106973 Related Classifications
Powered by Bioz